Darglitazone
From Wikipedia, the free encyclopedia
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | 141200-24-0  |
| PubChem (CID) | 60870 |
| ChemSpider | 54854  |
| UNII | AVP9C03Z3K |
| ChEMBL | CHEMBL55624 |
| Chemical and physical data | |
| Formula | C23H20N2O4S |
| Molar mass | 420.481 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.[1]
Its development was terminated on November 08, 1999.[2]
Synthesis[edit]
References[edit]
- ^ Hulin, Bernard; Clark, David A.; Goldstein, Steven W.; McDermott, Ruth E.; Dambek, Paul J.; Kappeler, Werner H.; Lamphere, Charles H.; Lewis, Diana M.; Rizzi, James P. (1992). "Novel thiazolidine-2,4-diones as potent euglycemic agents". Journal of Medicinal Chemistry. 35 (10): 1853–64. doi:10.1021/jm00088a022. PMID 1588563.
- ^ "Drug Profile: Darglitazone". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 28 November 2015.
